Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0508 Monotherapy and Combination with Olaparib in Advanced Solid Tumors
NCT06686745Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0508 in solid tumor (advanced stage), ovarian cancer, prostate cancer (PCa) and 2 more (3 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Dose-limiting toxicity. Started Dec 2024; status: recruiting.
02
Drugs
SIM0508
03
Conditions
solid tumor (advanced stage)ovarian cancerprostate cancer (PCa)breast cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06686745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06686745.